Allogene Therapeutics Files 2024 10-K
Ticker: ALLO · Form: 10-K · Filed: Mar 13, 2025 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | 10-K |
| Filed Date | Mar 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, biotechnology, financials
TL;DR
ALLO 10-K is in! Check financials for FY24.
AI Summary
Allogene Therapeutics, Inc. filed its 2024 10-K on March 13, 2025, reporting its fiscal year ended December 31, 2024. The company, focused on biological products, is headquartered in South San Francisco, California. The filing details its financial performance and business operations for the fiscal year.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Allogene Therapeutics' financial health and strategic direction for the past fiscal year, crucial for understanding its current market position and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Allogene Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-13 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-13 (date) — Filing date
- South San Francisco, CA (location) — Company headquarters
FAQ
What is the primary business of Allogene Therapeutics, Inc.?
Allogene Therapeutics, Inc. is primarily involved in the business of biological products, as indicated by its Standard Industrial Classification code [2836].
When did Allogene Therapeutics, Inc. file its 10-K report?
Allogene Therapeutics, Inc. filed its 10-K report on March 13, 2025.
What fiscal year does this 10-K filing cover?
This 10-K filing covers the fiscal year ended December 31, 2024.
Where is Allogene Therapeutics, Inc. headquartered?
Allogene Therapeutics, Inc. is headquartered at 210 East Grand Avenue, South San Francisco, CA 94080.
What is the SEC file number for Allogene Therapeutics, Inc.?
The SEC file number for Allogene Therapeutics, Inc. is 001-38693.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 13, 2025 regarding Allogene Therapeutics, Inc. (ALLO).